Higher Rate of Lymphedema with Inguinal versus Axillary Complete Lymph Node Dissection for Melanoma: A Potential Target for Immediate Lymphatic Reconstruction?

Melina Deban, Patrick Vallance, Evan Jost, J Gregory McKinnon, Claire Temple-Oberle, Melina Deban, Patrick Vallance, Evan Jost, J Gregory McKinnon, Claire Temple-Oberle

Abstract

Background: The present study was conducted to define the lymphedema rate at our institution in patients undergoing axillary (ALND) or inguinal (ILND) lymph node dissection (LND) for melanoma. It aimed to examine risk factors predisposing patients to a higher rate of lymphedema, highlighting which patients could be targeted for immediate lymphatic reconstruction (ILR).

Methods: A retrospective chart review was conducted between October 2015 and July 2020 to identify patients who had undergone ALND or ILND for melanoma. The main outcome measures were rates of transient and permanent lymphedema. Univariate and multivariate analyses were performed to assess the relationship between lymphedema rate and factors related to patient characteristics, surgical procedure, pathology findings, and adjuvant treatment.

Results: Between October 2015 and July 2020, 66 patients underwent LND for melanoma: 34 patients underwent ALND and 32 patients underwent ILND. At a median follow-up of 29 months, 85.3% (n = 29) of patients having had an ALND did not experience lymphedema, versus 50.0% (n = 16) of ILND (p = 0.0019). The rates of permanent lymphedema for patients having undergone ALND and ILND were 11.8% (n = 4) and 37.5% (n = 12) respectively (p = 0.016, NS). The rate of transient lymphedema was 2.9% (n = 1) for ALND and 12.5% (n = 4) for ILND (p = 0.13, NS). On univariate analysis, the location of LND and wound infection were found to be significant factors for lymphedema. On multivariate analysis, only the location of LND remained a significant predictor, with the inguinal location predisposing to lymphedema.

Conclusion: This study highlights the high rate of lymphedema following ILND for melanoma and is a potential target for future patients to be considered for ILR.

Trial registration: ClinicalTrials.gov NCT05136079.

Keywords: lymph node dissection; lymphatic reconstruction; lymphedema; melanoma.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. de Vries M., Hoekstra H.J., Hoekstra-Weebers J.E. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann. Surg. Oncol. 2009;16:2840–2847. doi: 10.1245/s10434-009-0602-6.
    1. Faries M.B., Thompson J.F., Cochran A.J., Andtbacka R.H., Mozzillo N., Zager J.S., Jahkola T., Bowles T.L., Testori A., Beitsch P.D., et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N. Engl. J. Med. 2017;376:2211–2222. doi: 10.1056/NEJMoa1613210.
    1. de Sire A., Losco L., Lippi L., Spadoni D., Kaciulyte J., Sert G., Ciamarra P., Marcasciano M., Cuomo R., Bolletta A., et al. Surgical Treatment and Rehabilitation Strategies for Upper and Lower Extremity Lymphedema: A Comprehensive Review. Medicina. 2022;58:954. doi: 10.3390/medicina58070954.
    1. Warren A.G., Brorson H., Borud L.J., Slavin S.A. Lymphedema: A comprehensive review. Ann. Plast. Surg. 2007;59:464–472. doi: 10.1097/01.sap.0000257149.42922.7e.
    1. Armer J.M., Stewart B.R. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res. Biol. 2005;3:208–217. doi: 10.1089/lrb.2005.3.208.
    1. Executive C. The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. Lymphology. 2016;49:170–184.
    1. Spillane A.J., Saw R.P., Tucker M., Byth K., Thompson J.F. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis. Ann. Surg. 2008;248:286–293. doi: 10.1097/SLA.0b013e31817ed7c3.
    1. Starritt E.C., Joseph D., McKinnon J.G., Lo S.K., de Wilt J.H., Thompson J.F. Lymphedema after complete axillary node dissection for melanoma: Assessment using a new, objective definition. Ann. Surg. 2004;240:866–874. doi: 10.1097/01.sla.0000143271.32568.2b.
    1. Lawenda B.D., Mondry T.E., Johnstone P.A. Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J. Clin. 2009;59:8–24. doi: 10.3322/caac.20001.
    1. Levenhagen K., Davies C., Perdomo M., Ryans K., Gilchrist L. Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline from the Oncology Section of the American Physical Therapy Association. Phys. Ther. 2017;97:729–745. doi: 10.1093/ptj/pzx050.
    1. Hidding J.T., Viehoff P.B., Beurskens C.H., van Laarhoven H.W., Nijhuis-van der Sanden M.W., van der Wees P.J. Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review. Phys. Ther. 2016;96:1965–1981. doi: 10.2522/ptj.20150412.
    1. Augustin M., Conde Montero E., Hagenstrom K., Herberger K., Blome C. Validation of a short-form of the Freiburg Life Quality Assessment for lymphoedema (FLQA-LS) instrument. Br. J. Dermatol. 2018;179:1329–1333. doi: 10.1111/bjd.16902.
    1. Devoogdt N., Van Kampen M., Geraerts I., Coremans T., Christiaens M.R. Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): Reliability and validity. Phys. Ther. 2011;91:944–957. doi: 10.2522/ptj.20100087.
    1. Klernas P., Johnsson A., Horstmann V., Kristjanson L.J., Johansson K. Lymphedema Quality of Life Inventory (LyQLI)-Development and investigation of validity and reliability. Qual. Life Res. 2015;24:427–439. doi: 10.1007/s11136-014-0783-8.
    1. Monticone M., Ferriero G., Keeley V., Brunati R., Liquori V., Maggioni S., Restelli M., Giordano A., Franchignoni F. Lymphedema quality of life questionnaire (LYMQOL): Cross-cultural adaptation and validation in Italian women with upper limb lymphedema after breast cancer. Disabil. Rehabil. 2021;44:4075–4080. doi: 10.1080/09638288.2021.1890842.
    1. Cormier J.N., Askew R.L., Mungovan K.S., Xing Y., Ross M.I., Armer J.M. Lymphedema beyond breast cancer: A systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116:5138–5149. doi: 10.1002/cncr.25458.
    1. Moody J.A., Botham S.J., Dahill K.E., Wallace D.L., Hardwicke J.T. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma—A systematic review of the literature. Eur. J. Surg. Oncol. 2017;43:1760–1767. doi: 10.1016/j.ejso.2017.07.003.
    1. Friedman J.F., Sunkara B., Jehnsen J.S., Durham A., Johnson T., Cohen M.S. Risk factors associated with lymphedema after lymph node dissection in melanoma patients. Am. J. Surg. 2015;210:1178–1184. doi: 10.1016/j.amjsurg.2015.08.014.
    1. Boccardo F., Casabona F., De Cian F., Friedman D., Villa G., Bogliolo S., Ferrero S., Murelli F., Campisi C. Lymphedema microsurgical preventive healing approach: A new technique for primary prevention of arm lymphedema after mastectomy. Ann. Surg. Oncol. 2009;16:703–708. doi: 10.1245/s10434-008-0270-y.
    1. Dean L.T., Moss S.L., Ransome Y., Frasso-Jaramillo L., Zhang Y., Visvanathan K., Nicholas L.H., Schmitz K.H. "It still affects our economic situation": Long-term economic burden of breast cancer and lymphedema. Support. Care Cancer. 2019;27:1697–1708. doi: 10.1007/s00520-018-4418-4.
    1. Bowman C., Piedalue K.A., Baydoun M., Carlson L.E. The Quality of Life and Psychosocial Implications of Cancer-Related Lower-Extremity Lymphedema: A Systematic Review of the Literature. J. Clin. Med. 2020;9:3200. doi: 10.3390/jcm9103200.
    1. Taghian N.R., Miller C.L., Jammallo L.S., O’Toole J., Skolny M.N. Lymphedema following breast cancer treatment and impact on quality of life: A review. Crit. Rev. Oncol. Hematol. 2014;92:227–234. doi: 10.1016/j.critrevonc.2014.06.004.
    1. Sars C., Gillgren P., Schultz I., Lindqvist E.K. Risk Factors for Complications and Long-Term Outcomes Following Completion Lymph Node Dissection for Cutaneous Melanoma: A Retrospective Cohort Study. J. Plast. Reconstr. Aesthet. Surg. 2020;73:1540–1546. doi: 10.1016/j.bjps.2020.02.038.
    1. Gjorup C.A., Dahlstroem K., Hendel H.W., Drzewiecki K.T., Klausen T.W., Holmich L.R. Factors associated with melanoma-related limb lymphoedema. Acta Oncol. 2021;60:779–784. doi: 10.1080/0284186X.2021.1905175.
    1. Jorgensen M.G., Toyserkani N.M., Thomsen J.B., Sorensen J.A. Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients. J. Plast. Reconstr. Aesthet. Surg. 2018;71:590–596. doi: 10.1016/j.bjps.2017.11.026.
    1. Serpell J.W., Carne P.W., Bailey M. Radical lymph node dissection for melanoma. ANZ J. Surg. 2003;73:294–299. doi: 10.1046/j.1445-2197.2003.t01-1-02622.x.
    1. Jorgensen M.G., Toyserkani N.M., Sorensen J.A. The effect of prophylactic lymphovenous anastomosis and shunts for preventing cancer-related lymphedema: A systematic review and meta-analysis. Microsurgery. 2018;38:576–585. doi: 10.1002/micr.30180.
    1. Cakmakoglu C., Kwiecien G.J., Schwarz G.S., Gastman B. Lymphaticovenous Bypass for Immediate Lymphatic Reconstruction in Locoregional Advanced Melanoma Patients. J. Reconstr. Microsurg. 2020;36:247–252. doi: 10.1055/s-0039-3401829.
    1. Chungsiriwattana W., Kongkunnavat N., Kamnerdnakta S., Hayashi A., Tonaree W. Immediate inguinal lymphaticovenous anastomosis following lymphadenectomy in skin cancer of lower extremities. Asian J. Surg. 2022. in press .
    1. Reticker-Flynn N.E., Zhang W., Belk J.A., Basto P.A., Escalante N.K., Pilarowski G.O.W., Bejnood A., Martins M.M., Kenkel J.A., Linde I.L., et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185:1924–1942. doi: 10.1016/j.cell.2022.04.019.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel